A Double-blind, Randomised, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalised for Acute Heart Failure

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalised for Acute Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Decompensated heart failure; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms ATOMIC-AHF
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2016 Results published in the Journal of the American College of Cardiology
    • 23 Sep 2013 Additional results presented at a late-breaking clinical trials session at the Heart Failure Society of America Annual Scientific meeting, according to a Cytokinetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top